February 14, 2023
1 min watch
Save
VIDEO: Irinotecan liposome regimen promising in first-line metastatic pancreatic cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.
The data showed that irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin — a regimen also known as NALIRIFOX — prolonged OS and PFS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma.
“It’s really nice to see this — makes things clearer as to what we should be giving in the first-line systemic setting in metastatic pancreatic cancer,” Monge said.
Reference:
- Wainberg ZA, et al. Abstract LBA661. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Monge is the recipient of the Winn Career Development Award.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.